Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and src family kinase YES in rhabdomyosarcoma
…, J Derdak, H Lei, A Pan, E Dombi, I Palacio-Yance… - Clinical cancer …, 2023 - AACR
… phase I study of the IGF-1R antibody cixutumumab plus the mTOR inhibitor temsirolimus in
patients with metastatic prostate cancer, reported grade 1 or 2 … dasatinib plus gemcitabine …
patients with metastatic prostate cancer, reported grade 1 or 2 … dasatinib plus gemcitabine …
[HTML][HTML] Chemotherapy and targeted therapy with management of related complications in pancreatic cancer
KH Lee - The Korean Journal of Pancreas and Biliary Tract, 2015 - kjpbt.org
… , only erlotinib – a small molecular inhibitor of the epidermal … the targeted therapy for metastatic
pancreatic cancer. In this … with gemcitabine plus placebo in advanced pancreatic cancer…
pancreatic cancer. In this … with gemcitabine plus placebo in advanced pancreatic cancer…
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
C Gridelli, A Rossi, MA Bareschino… - Expert opinion on …, 2010 - Taylor & Francis
… IMC-A12 (cixutumumab), a fully human IgG1 mAb that binds … Phase II randomized trial
comparing erlotinib versus erlotinib … combination of carboplatin plus gemcitabine with or without …
comparing erlotinib versus erlotinib … combination of carboplatin plus gemcitabine with or without …
Novel Targeted Treatment Approaches in Pancreatic Cancer
M Diab, MS Hamid, RM Mohammad, PA Philip… - Textbook of …, 2019 - Springer
… cixutumumab, another IGF1R monoclonal antibody antagonist, with erlotinib and GEM failed
to show a … Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib …
to show a … Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib …
Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials
… for which an anti-programmed death receptor 1 (PD-1) antibody … of these growth factors
include insulin-like growth factors, … erlotinib, cixutumumab, and gemcitabine versus gemcitabine …
include insulin-like growth factors, … erlotinib, cixutumumab, and gemcitabine versus gemcitabine …
[HTML][HTML] Pancreatic ductal adenocarcinoma: current and evolving therapies
A Adamska, A Domenichini, M Falasca - International journal of molecular …, 2017 - mdpi.com
… Phase II and phase III trial assessing the role of erlotinib in … antibodies ganitumab and
cixutumumab have been evaluated; … Programmed death receptor 1 (PD-1), a well as its ligand PD-…
cixutumumab have been evaluated; … Programmed death receptor 1 (PD-1), a well as its ligand PD-…
[HTML][HTML] Therapeutic application of monoclonal antibodies in pancreatic cancer: advances, challenges and future opportunities
GA Arias-Pinilla, H Modjtahedi - Cancers, 2021 - mdpi.com
… domain of the type I insulin-like growth factor receptor (IGF-IR), … On the other hand,
cixutumumab (IMC-A12), a fully human … erlotinib and gemcitabine in a phase 1b/2 study in …
cixutumumab (IMC-A12), a fully human … erlotinib and gemcitabine in a phase 1b/2 study in …
[HTML][HTML] Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
GL Deng, S Zeng, H Shen - World journal of hepatology, 2015 - ncbi.nlm.nih.gov
… (gemcitabine, oxaliplatin and capecitabine) or erlotinib in … the EGFR/human epidermal-growth-factor
receptor 1 (HER1) … also reported from a phase II clinical trial of cixutumumab (IMC-…
receptor 1 (HER1) … also reported from a phase II clinical trial of cixutumumab (IMC-…
Molecular targeted approaches for treatment of pancreatic cancer
… refractory and metastatic pancreatic cancer patients was carried out [… erlotinib plus IMC-A12
(cixutumumab) versus gemcitabine … anti-insulin-like growth factor receptor type I monoclonal …
(cixutumumab) versus gemcitabine … anti-insulin-like growth factor receptor type I monoclonal …
[HTML][HTML] … , a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial …
GE Konecny, AEW Hendrickson, TM Davidson… - Gynecologic …, 2021 - Elsevier
… of the insulin-like growth factor 1 receptor (IGF-1R) signaling … AKT and ERK1/2, proliferation,
migration and metastasis. An … combination with gemcitabine in pancreatic cancer has shown …
migration and metastasis. An … combination with gemcitabine in pancreatic cancer has shown …